Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or planned new fundraising through debt or equity in the excerpts. The company has been systematically repaying loans using IPO proceeds (INR 195 crores repaid across FY '25 and H1 FY '26). Finance costs have improved due to repayments and reduced interest on deferred acquisition-related payments. CapEx plans for FY '27 include INR 380-400 crores for new facilities and CMS facility, funded presumably through internal cash flows and existing resources. Acquisition-related payments scheduled for INR 60-65 crores in FY '27. No mention of any new debt or

Any current/future capex/capital investment/strategic investment?

For FY '27, Dr. Agarwal's Healthcare Limited plans a total capex of approximately INR 380 to 400 crores. This includes the addition of 60 new facilities: 40 surgical centers and 20 clinics. Capex also covers the establishment of a new CMS (Centralized Medical Services) facility. The new CMS facility expected to commission by October 1, 2026, pending approvals. Acquisition-related payments for FY '27 are expected to be around INR 60-65 crores. The company focuses on organic growth but remains open to partnerships if aligned strategically and financially. Additional capex will involve costs rela

Future growth expectations in sales/revenue/volumes?

Growth expected to sustain at a similar pace as FY '26, driven by deeper penetration of existing micro markets and expansion into new geographies. (Page 7, 8) Accelerated adoption of innovative surgical procedures and advanced technologies to enhance service offerings. (Page 7, 8) FY '27 facility addition plan includes commissioning 60 new facilities (40 surgical centers, 20 clinics), mostly organic growth. (Page 17, 18) North region (including Delhi NCR) expected to see highest ever addition of 16 facilities, with rapid build-out in micro markets including Noida, Ghaziabad, and key towns i

Future growth expectations in earnings/operating earnings/profits/EPS?

Expectation of sustaining growth pace similar to FY '26, underpinned by: - Deeper penetration in existing micro markets - Expansion into new geographies including strong focus on North India (Delhi, Gurgaon) - Accelerated adoption of innovative surgical procedures and advanced technologies EBITDA margins expected to remain stable despite aggressive greenfield expansion, reflecting operating leverage Mature facilities showing sustainable growth with 14% same-store sales growth (SSSG) split evenly between volume and value (7% each), with continued premiumization and price hikes contribut

Current/ Expected Orderbook/ Pending Orders?

For acquisition-related payments pending post FY '26: - FY '27 expected payout: ~INR 65 crores - FY '28, '29, and small payments in '30 combined: ~INR 60-66 crores No specific mention of a traditional "order book" as the company operates in healthcare services, not manufacturing. The company is focused on organic growth with plans to open 40 surgical centers and 20 clinics in FY '27. They continue to explore partnerships if aligned and reasonably priced, but these are not included in the current pipeline. Project completion update: New facility in Chennai targeted for launch by October 1,

IN US

Sale is live|00:00:00left today

Dr Agarwals Health Care LtdQ1 FY26Healthcare Services

Dr Agarwals Health Care Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹477P/E: 111.9Market Cap: ₹14.3K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

→Growth expected to sustain at a similar pace as FY '26, driven by deeper penetration of existing micro markets and expansion into new geographies. (Page 7, 8)
→Accelerated adoption of innovative surgical procedures and advanced technologies to enhance service offerings. (Page 7, 8)
→FY '27 facility addition plan includes commissioning 60 new facilities (40 surgical centers, 20 clinics), mostly organic growth. (Page 17, 18)
→North region (including Delhi NCR) expected to see highest ever addition of 16 facilities, with rapid build-out in micro markets including Noida, Ghaziabad, and key towns in Haryana. (Page 7)
→Mumbai region to be a key focus area for aggressive scaling in FY '27 due to strong traction of recent facilities. (Page 6)
→Refractive surgeries expected to grow long term, supported by potential insurance partnerships and premiumization of procedures. (Page 18)
→Overall volume growth in FY '26 was ~7%, value (realization) growth also ~7%, indicating balanced growth. (Page 16, 14)
→OPD growth, premiumization, and price hikes expected to contribute to sustained revenue growth. (Page 16)

Margin guidance

Category 3

→Expectation of sustaining growth pace similar to FY '26, underpinned by:
→ - Deeper penetration in existing micro markets
→ - Expansion into new geographies including strong focus on North India (Delhi, Gurgaon)
→ - Accelerated adoption of innovative surgical procedures and advanced technologies
→EBITDA margins expected to remain stable despite aggressive greenfield expansion, reflecting operating leverage
→Mature facilities showing sustainable growth with 14% same-store sales growth (SSSG) split evenly between volume and value (7% each), with continued premiumization and price hikes contributing to margin improvement
→New branches currently incurring losses (~INR 30 crores in FY '26) but losses per branch expected to reduce from FY '27 onward as brand presence strengthens
→Continuous reduction in finance costs due to loan repayments and lower interest on deferred acquisition payments
→Overall, profitability expected to improve driven by operational efficiencies, network scale, and premium offerings supporting EPS growth.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no explicit mention of any current or planned new fundraising through debt or equity in the excerpts.
→The company has been systematically repaying loans using IPO proceeds (INR 195 crores repaid across FY '25 and H1 FY '26).
→Finance costs have improved due to repayments and reduced interest on deferred acquisition-related payments.
→CapEx plans for FY '27 include INR 380-400 crores for new facilities and CMS facility, funded presumably through internal cash flows and existing resources.
→Acquisition-related payments scheduled for INR 60-65 crores in FY '27.
→No mention of any new debt or equity issuance or capital raising plans in the near term.

Order book

→For acquisition-related payments pending post FY '26:
→ - FY '27 expected payout: ~INR 65 crores
→ - FY '28, '29, and small payments in '30 combined: ~INR 60-66 crores
→No specific mention of a traditional "order book" as the company operates in healthcare services, not manufacturing.
→The company is focused on organic growth with plans to open 40 surgical centers and 20 clinics in FY '27.
→They continue to explore partnerships if aligned and reasonably priced, but these are not included in the current pipeline.
→Project completion update: New facility in Chennai targeted for launch by October 1, 2026.
→Merger-related approvals progressing, with shareholders' meetings set for July 2, 2026, and final merger completion expected by Q3 FY '27 (around end of the calendar year).

Capex plans

Yes

→For FY '27, Dr. Agarwal's Healthcare Limited plans a total capex of approximately INR 380 to 400 crores.
→This includes the addition of 60 new facilities: 40 surgical centers and 20 clinics.
→Capex also covers the establishment of a new CMS (Centralized Medical Services) facility.
→The new CMS facility expected to commission by October 1, 2026, pending approvals.
→Acquisition-related payments for FY '27 are expected to be around INR 60-65 crores.
→The company focuses on organic growth but remains open to partnerships if aligned strategically and financially.
→Additional capex will involve costs related to real estate acquisition and compliance for new centers.
→The corporate office rental expense is ongoing and part of operational investment.

How does Dr Agarwals Health Care Ltd rank vs peers in Healthcare Services?

Pro feature

1Dr Agarwals Health Care Ltd

Rev 2Mar 3

See full Healthcare Services sector rankings

Want more stocks like Dr Agarwals Health Care Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio